Table 3.
Change in antidiabetic treatment from before initiation of liraglutide to the end of study
| Before initiation of liraglutide (FAS) | Before initiation of liraglutide (EAS) | At end of inclusion (0 months) (FAS) | At end of inclusion (0 months) (EAS) | At end of study (2 years) (FAS/EAS)a | |
|---|---|---|---|---|---|
| Therapeutic strategy | |||||
| Monotherapy | 609 (19.5) | 409 (20.4) | 121 (3.9) | 75 (3.8) | 68 (3.8) |
| Double therapy | 1233 (39.5) | 821 (40.9) | 1181 (38.2) | 795 (39.9) | 621 (34.8) |
| Triple therapy | 1090 (34.9) | 667 (33.2) | 1415 (45.8) | 888 (44.6) | 733 (41.0) |
| >3 triple therapy | 188 (6.0) | 112 (5.6) | 372 (12.0) | 234 (11.7) | 365 (20.4) |
| Treatments | |||||
| Biguanides | 2561 (82.1) | 1668 (83.0) | 2521 (81.6) | 1648 (82.7) | 1623 (82.5) |
| SUs | 1780 (57.1) | 1131 (56.3) | 1596 (51.6) | 992 (49.7) | 1002 (50.9) |
| DPP-4 inhibitors | 1261 (40.4) | 805 (40.1) | 257 (8.3) | 182 (9.1) | 191 (9.7) |
| Insulin | 488 (15.6) | 260 (12.9) | 283 (9.1) | 165 (8.3) | 440 (24.0) |
| Glitazones | 425 (13.6) | 284 (14.1) | 190 (6.1) | 121 (6.1) | 60 (3.0) |
| Glinides | 277 (8.9) | 158 (7.9) | 221 (7.1) | 124 (6.2) | 172 (8.7) |
| Alpha-glucosidase inhibitors | 160 (5.1) | 100 (5.0) | 90 (2.9) | 61 (3.1) | 76 (3.9) |
| Total analyzed | 3120 (100) | 2009 (100) | 3089 (100) | 1992 (100) | 1787 (100) |
DPP-4 dipeptidyl peptidase-4, EAS effectiveness analysis set, FAS full analysis set, n number for subset, SU Sulfonylurea
aThere were the same number of patients still remaining in both FAS and EAS populations at the end of the study; therefore, the percentages are the same in both populations. Values are expressed as n (%). Due to missing data, the % value relates to the number of patients analyzed within the FAS or EAS population for that particular time point and not the total FAS or EAS population